The Incidence and Risk Factors for Clostridioides Difficle Infection in Solid Organ Transplant Recipients
NCT ID: NCT04637321
Last Updated: 2022-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
585 participants
OBSERVATIONAL
2019-11-04
2020-08-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Primary Objective(s)
* Identify the incidence and risk of CDI within one year after kidney, liver, and/or pancreas transplant
* Secondary Objective(s)
* Identify the risk factors for recurrent CDI post-transplant in patients who were diagnosed with a CDI within one year prior to Solid Organ Transplant
* Evaluate the impact of CDI on graft survival following Solid Organ Transplant
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Changes in Recipients Gut Microbiota After Fecal Microbiota Transplantation
NCT05739825
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
NCT07250724
Digestive Microbiota Transplant
NCT03606031
Early FMT for C.Difficile
NCT02465463
Fecal Transplant for Relapsing C. Difficile Infection
NCT01703494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018
* Will analyze outcomes from April 1, 2014 to July 31, 2019
* Patient list will be generated in Epic and Meditech
* All data will be obtained from Epic and Meditech
* All data will be collected retrospectively after the patient is discharged from the hospital
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Solid organ transplant
Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>18 years old
Exclusion Criteria
* Loss to early death defined as within one week from transplantation
* Patients whose primary address is in Puerto Rico
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Methodist Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jessica Crotty, PharmD
Role: PRINCIPAL_INVESTIGATOR
The Methodist Hospital Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jessica Rago
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
059.PHA.2019.D
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.